Cardiotoxicity Associated with Targeted Cancer Therapies

Overview

Journal Mol Clin Oncol

Specialty Oncology

Date 2016 Apr 29

PMID 27123262

Citations 35

Authors

Z I Chen

D I Ai

Affiliations

Soon will be listed here.

Abstract

Compared with traditional chemotherapy, targeted cancer therapy is a novel strategy in which key molecules in signaling pathways involved in carcinogenesis and tumor spread are inhibited. Targeted cancer therapy has fewer adverse effects on normal cells and is considered to be the future of chemotherapy. However, targeted cancer therapy-induced cardiovascular toxicities are occasionally critical issues in patients who receive novel anticancer agents, such as trastuzumab, bevacizumab, sunitinib and imatinib. The aim of this review was to discuss these most commonly used drugs and associated incidence of cardiotoxicities, including left ventricular dysfunction, heart failure, hypertension and thromboembolic events, as well as summarize their respective molecular mechanisms of cardiovascular adverse effects.

Citing Articles

A meta-analysis on the impact of concurrent or pre-existing cancer diagnosis on acute myocardial infarction outcomes.

Wang J, Yu J PLoS One. 2025; 20(1):e0318437.

PMID: 39888923 PMC: 11785289. DOI: 10.1371/journal.pone.0318437.

From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond.

Zhou Y, Yao Z, Lin Y, Zhang H Pharmaceutics. 2024; 16(7).

PMID: 39065585 PMC: 11279542. DOI: 10.3390/pharmaceutics16070888.

Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON).

Tobias J, Maglakelidze M, Andric Z, Ryspayeva D, Bulat I, Nikolic I Clin Cancer Res. 2024; 30(18):4044-4054.

PMID: 39028916 PMC: 11393538. DOI: 10.1158/1078-0432.CCR-24-0742.

Paclitaxel-induced myocarditis presenting as new-onset heart failure.

Johnson D, Weisleder H, Yuan H, Carrozzi G BMJ Case Rep. 2024; 17(1).

PMID: 38176758 PMC: 10773322. DOI: 10.1136/bcr-2023-255646.

Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer.

Rocca C, Soda T, De Francesco E, Fiorillo M, Moccia F, Viglietto G J Transl Med. 2023; 21(1):635.

PMID: 37726810 PMC: 10507834. DOI: 10.1186/s12967-023-04498-5.

References

DeVita Jr V, Chu E . A history of cancer chemotherapy. Cancer Res. 2008; 68(21):8643-53. DOI: 10.1158/0008-5472.CAN-07-6611. View

Pande A, Lombardo J, Spangenthal E, Javle M . Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res. 2007; 27(5B):3465-70. View

Kuenen B, Levi M, Meijers J, Kakkar A, van Hinsbergh V, Kostense P . Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol. 2002; 22(9):1500-5. DOI: 10.1161/01.atv.0000030186.66672.36. View

Sawyers C . Targeted cancer therapy. Nature. 2004; 432(7015):294-7. DOI: 10.1038/nature03095. View

Motzer R, Hutson T, Tomczak P, Michaelson M, Bukowski R, Rixe O . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2):115-24. DOI: 10.1056/NEJMoa065044. View

Latif Z, Watters A, Bartlett J, Underwood M, Aitchison M . Gene amplification and overexpression of HER2 in renal cell carcinoma. BJU Int. 2002; 89(1):5-9. View

Cheng H, Force T . Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res. 2010; 106(1):21-34. DOI: 10.1161/CIRCRESAHA.109.206920. View

Nalluri S, Chu D, Keresztes R, Zhu X, Wu S . Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008; 300(19):2277-85. DOI: 10.1001/jama.2008.656. View

Cohen M, Williams G, Johnson J, Duan J, Gobburu J, Rahman A . Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002; 8(5):935-42. View

10.

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

11.

Bearzi C, Rota M, Hosoda T, Tillmanns J, Nascimbene A, De Angelis A . Human cardiac stem cells. Proc Natl Acad Sci U S A. 2007; 104(35):14068-73. PMC: 1955818. DOI: 10.1073/pnas.0706760104. View

12.

Clynes R, Towers T, Presta L, Ravetch J . Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6(4):443-6. DOI: 10.1038/74704. View

13.

Whittle B, Moncada S, Vane J . Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins. 1978; 16(3):373-88. DOI: 10.1016/0090-6980(78)90216-2. View

14.

Schuell B, Gruenberger T, Scheithauer W, Zielinski C, Wrba F . HER 2/neu protein expression in colorectal cancer. BMC Cancer. 2006; 6:123. PMC: 1475876. DOI: 10.1186/1471-2407-6-123. View

15.

Karp J, Gojo I, Pili R, Gocke C, Greer J, Guo C . Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res. 2004; 10(11):3577-85. DOI: 10.1158/1078-0432.CCR-03-0627. View

16.

van Dalen E, Michiels E, Caron H, Kremer L . Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2006; (4):CD005006. DOI: 10.1002/14651858.CD005006.pub2. View

17.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

18.

Perez E, Koehler M, Byrne J, Preston A, Rappold E, Ewer M . Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008; 83(6):679-86. DOI: 10.4065/83.6.679. View

19.

Bristow M, Thompson P, Martin R, Mason J, Billingham M, Harrison D . Early anthracycline cardiotoxicity. Am J Med. 1978; 65(5):823-32. DOI: 10.1016/0002-9343(78)90802-1. View

20.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View